Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Time Course of the Antiproteinuric and Blood Pressure Lowering Effects After Initiation of Renin Inhibition With Aliskiren in Type 2 Diabetes

This study has been completed.
Sponsor:
Information provided by:
Novartis
ClinicalTrials.gov Identifier:
NCT00461136
First received: April 16, 2007
Last updated: September 22, 2016
Last verified: September 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: November 2006
  Primary Completion Date: November 2006 (Final data collection date for primary outcome measure)